Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1960 1
1966 1
1967 2
1968 1
1973 1
1974 1
1977 2
1978 6
1980 4
1981 4
1983 2
1984 2
1985 11
1986 41
1987 362
1988 956
1989 1143
1990 1338
1991 1296
1992 1382
1993 1375
1994 1349
1995 1487
1996 1644
1997 1851
1998 2056
1999 2159
2000 2320
2001 2502
2002 2789
2003 3358
2004 3674
2005 4231
2006 4714
2007 4940
2008 5705
2009 5892
2010 7049
2011 7851
2012 9028
2013 9926
2014 10501
2015 11789
2016 11753
2017 11438
2018 11286
2019 6083
2020 193
Text availability
Article attribute
Article type
Publication date

Search Results

139,873 results
Results by year
Filters applied: . Clear all
Page 1
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y, et al. J Exp Clin Cancer Res 2019 - Review. PMID 31500650 Free PMC article.
Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the third leading cause of tumor-related mortality worldwide. ...As an inflammation-associated tumor, it's well-evidenced that the immunosuppressive microenvironment of HCC can promote immune tolerance and evasion by various mechanisms. ...
Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the third leading cause of tumor-related mortality …
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Razavi P, et al. Nat Med 2019 - Clinical Trial. PMID 31768066
Accurate identification of tumor-derived somatic variants in plasma circulating cell-free DNA (cfDNA) requires understanding of the various biological compartments contributing to the cfDNA pool. ...The assay displayed high sensitivity and specificity, allowing for de novo detection of tumor-derived mutations and inference of tumor mutational burden, microsatellite instability, mutational signatures and sources of somatic mutations identified in cfDNA. ...
Accurate identification of tumor-derived somatic variants in plasma circulating cell-free DNA (cfDNA) requires understanding of the v …
A clonal expression biomarker associates with lung cancer mortality
Biswas D, et al. Nat Med 2019. PMID 31591602 Free PMC article.
An aim of molecular biomarkers is to stratify patients with cancer into disease subtypes predictive of outcome, improving diagnostic precision beyond clinical descriptors such as tumor stage(1). ...Clonal transcriptomic biomarkers overcome tumor sampling bias, associate with survival independent of clinicopathological risk factors, and may provide a general strategy to refine biomarker design across cancer types....
An aim of molecular biomarkers is to stratify patients with cancer into disease subtypes predictive of outcome, improving diagnostic …
The Role of Exosomes in Pancreatic Cancer
Lan B, et al. Int J Mol Sci 2019 - Review. PMID 31487880 Free PMC article.
Additionally, they have been verified to be potential as biomarkers, targets and drug carriers for pancreatic cancer treatment. ...
Additionally, they have been verified to be potential as biomarkers, targets and drug carriers for pancreatic cancer treatment. ...
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
Gelsomino F, et al. Cancer Treat Rev 2019 - Review. PMID 31491661
Predictive factors from these trials are reviewed in order to identify their clinical value, with particular emphasis on PD-L1 expression on both tumor cells and in stroma, especially in pembrolizumab-treated patients, and tumor mutational burden, for patients treated with the ipilimumab and nivolumab combination....
Predictive factors from these trials are reviewed in order to identify their clinical value, with particular emphasis on PD-L1 expression on …
Broccoli or Sulforaphane: Is It the Source or Dose That Matters?
Yagishita Y, et al. Molecules 2019 - Review. PMID 31590459 Free PMC article.
More effort is required to elucidate underlying mechanisms of action and to develop and validate biomarkers of pharmacodynamic action in humans. ...
More effort is required to elucidate underlying mechanisms of action and to develop and validate biomarkers of pharmacodynamic action …
Tumor-suppressive circular RNAs: Mechanisms underlying their suppression of tumor occurrence and use as therapeutic targets.
Li Z, et al. Cancer Sci 2019 - Review. PMID 31599076 Free PMC article.
Those circRNAs with tumor-suppressive properties play an important role in tumorigenesis and metastasis and thus may be used as therapeutic targets of cancers. ...Thanks to their structural stability, these tumor-suppressive circRNAs may be used as potential and potent therapeutic targets. ...
Those circRNAs with tumor-suppressive properties play an important role in tumorigenesis and metastasis and thus may be used as thera …
Extracellular Matrix Alterations in Metastatic Processes
Paolillo M and Schinelli S. Int J Mol Sci 2019 - Review. PMID 31591367 Free PMC article.
During cancer progression, epithelial tumor cells may undergo epithelial-to-mesenchymal transition (EMT), a morphological and functional remodeling, that deeply alters tumor cell features, leading to loss of epithelial markers (i.e., E-cadherin), changes in cell polarity and intercellular junctions and increase of mesenchymal markers (i.e., N-cadherin, fibronectin and vimentin). ...Moreover, the functional role of cells forming the tumor niche will also be reviewed in light of the most recent findings....
During cancer progression, epithelial tumor cells may undergo epithelial-to-mesenchymal transition (EMT), a morphological and functio …
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Hamaguchi T, et al. Cancer Sci 2019 - Clinical Trial. PMID 31520559 Free PMC article.
Seventy-eight potential protein biomarkers were chosen for analysis based on their roles in angiogenesis, tumor progression, and tumor-stroma interaction. ...None correlated with progression-free survival or maximum tumor shrinkage. Pre-dose 3 levels did not correlate with any efficacy endpoints. ...
Seventy-eight potential protein biomarkers were chosen for analysis based on their roles in angiogenesis, tumor progression, a …
139,873 results
Jump to page
Feedback